AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03452618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: diagnosis variables
Description: The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~* Age of the patient~* Sex~* Presence of bulbar involvement or not~* Time from onset of first symptoms to diagnosis of ALS~* Score ALSFRS-R~* Presence of another underlying respiratory pathology (COPD, asthma ...)~* FVC measurement (Forced vital capacity)~* PaCO2 measurement~* Measure SNIP (Sniff nasal inspiratory pressure)~* Measure of Pimax (Pressure inspiratory maximal)~* Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)
Study NCT03452618 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: diagnosis variables
Description: The study compare the diagnostic variables in patients who received Non invasive ventilation equipment one year after diagnosis with the patient who don't need it. For the independent variables, the present study determine a threshold at the diagnosis for which an early fitting risk appears~The diagnostic variable are :~* Age of the patient~* Sex~* Presence of bulbar involvement or not~* Time from onset of first symptoms to diagnosis of ALS~* Score ALSFRS-R~* Presence of another underlying respiratory pathology (COPD, asthma ...)~* FVC measurement (Forced vital capacity)~* PaCO2 measurement~* Measure SNIP (Sniff nasal inspiratory pressure)~* Measure of Pimax (Pressure inspiratory maximal)~* Measurement of the nocturnal desaturation index (number of desaturation less than 90% per hour of sleep)
Study NCT00190242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: group1
Description: Havrix at 1440IU was administrated à weeks S0, S4 and S24
Study NCT00190242 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group2
Description: Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
Study NCT03016338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 200 or 300 mg daily PO, for 21 day cycle
Study NCT03016338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TSR-042
Description: 500 mg once intravenously on day 1 of cycle (From cycle 1-4 followed by 1000 mg intravenously every 6 weeks for maximum of 2 yrs)
Study NCT02036450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable loop recorder (Medtronic Reveal LINQ(TM))
Description: The patients in the experimental arm receive an implantable loop recorder (Medtronic Reveal LINQ(TM)) with continuous monitoring, and are followed by daily automated remote transmissions. New arrhythmia episodes are reviewed daily by an experienced medical doctor. If AF lasting ≥6 minutes is detected and confirmed by at least two senior cardiologists, OAC is initiated. Decision about specific type of OAC, and possible further clinical work-up or treatment, is left to the treating physician and the patient. The remote monitoring continues until end of service of the device, patient withdrawal or other end-of-study.
Study NCT01973452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Study NCT02504723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure >90 mm Hg.
Study NCT02504723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyanoacrylate
Description: The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
Study NCT01246960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Administered intravenously
Study NCT00716820 — intervention group
Intervention type: DRUG
Intervention: SUNITINIB MALATE
Description: SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.~The dosage may be decreased according to the patient's clinical condition.
Study NCT03738917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan 15 milligrams
Description: This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
Study NCT01973452 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03738917 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipratropium Bromide 20Micrograms Inhaler
Description: This drug is already marketed, and therefore, the manufacturer is responsible for the elaboration and control of samples. This study drug will be provided free to the participants by the sponsor.
Study NCT03738917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Honey 30 g (full tablespoon)
Description: This study product will be provided free to the participants by the sponsor.
Study NCT03738917 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual clinical practice
Description: Clinicians will not be allowed to prescribe antitussives, including codeine, anticholinergic inhalers and they will not be allowed to recommend the use of honey.
Study NCT04636632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fosaprepitant
Description: fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
Study NCT03400254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gedatolisib
Description: Gedatolisib will be administered intravenously on a weekly dosing schedule at 150 mg IV.~Within 3 days prior to GED dosing the patient must have an ANC >1.0 x 109/L and platelet count > 75 x 109/L. If hematologic toxicity persists, treatment should be delayed by one week and the complete blood cell count with differential and platelet count repeated. Treatment may be delayed for up to 4 consecutive weeks (28 days). If after 28 days of delay all hematologic toxicity has still not resolved to normal and non-hematologic toxicity has not resolved to \<grade 1 then any further treatment with GED should be stopped.
Study NCT04636632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosaprepitant
Description: fosaprepitant 150mg/m2 weekly or triweekly during concurrent chemoradiotherapy
Study NCT04127318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedaling Group
Description: Participants will pedal at low-moderate intensity using a stationary pedal ergometer concurrent to their immunotherapy infusion (30 minutes).
Study NCT01746524 — intervention group
Intervention type: DEVICE
Intervention: ATTUNE Primary Total Knee Arthroplasty
Description: Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
Study NCT02172729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adductor canal block with 20 ml lidocaine, single bolus
Description: Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
Study NCT04760873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: cryotherapy is a freeze spray that will be applied to GAVE for bleeding
Study NCT01185249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weigh subjects on a scale in the standing position
Description: Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
Study NCT04245527 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Joovv Infrared Light Device
Description: Joovv is the leading manufacturer of personal, in-home red light therapy devices
Study NCT01789853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Walking
Description: 8 weeks high intensity walking training over multiple stepping tasks
Study NCT01789853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Regular physical therapy for 8 weeks
Study NCT00302718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-level financial incentives
Description: Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
Study NCT00302718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice-level financial incentives
Description: Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
Study NCT00302718 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician- and practice-level financial incentives
Description: Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
Study NCT03440385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Specified dose on specified days
Study NCT03440385 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT03521193 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patent foramen ovale closure
Description: Pts undergoing PFO closure will receive 2-months of DAPT and 6 months of aspirin after patent foramen ovale (PFO) closure; they will be compared to healthy subjects on aspirin treatment
Study NCT02207296 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Plethysmographic variability index
Study NCT00530309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK716155 for injection
Description: GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
Study NCT04633330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AHCC®capsules
Description: AHCC®capsules, a standardized extract of cultured Lentinula edodes mycelia (ECLM) TID for 6 months after enrolment.
Study NCT04633330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simulation of AHCC®capsules
Description: TID for 6 months after enrolment. A compensation of AHCC®is provided to participant from control arm when HR-HPV positive at 6 months after enrolment.
Study NCT00027599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00027599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prostatic acid phosphatase-sargramostim fusion protein
Study NCT00027599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sipuleucel-T
Study NCT00027599 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Study NCT00027599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro-treated peripheral blood stem cell transplantation
Study NCT00642486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)
Description: portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.
Study NCT00642486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard polysomnography (PSG)
Description: laboratory-based testing
Study NCT01599286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbaglu
Description: Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)~The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients >15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.~The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.
Study NCT01599286 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo that looks/tastes the same as NCG and is administered on the same schedule as the NCG intervention
Study NCT00871026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthodontic treatment with customized archwires
Description: orthodontic treatment with customized archwires
Study NCT00871026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic treatment with prefabricated archwires
Description: orthodontic treatment with prefabricated archwires
Study NCT01480687 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA-EPA
Description: 1800 mg/day
Study NCT00530309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo.
Study NCT05300061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personal Values Intervention
Description: A 15 minute personal values intervention. Aim is to help participants clarify their own values around flying and promote committed action towards airplanes.
Study NCT05300061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosocial Values Intervention
Description: A 15 minute prosocial values intervention. Aim is to help participants clarify their prosocial values around flying and promote committed action towards airplanes.
Study NCT00944333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 300-600 loading dose 75 mg/die for 6 months
Study NCT00944333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 300-600 loading dose 75 mg/die for 12 months
Study NCT02618018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AT TORBI 709M
Description: Cataract surgery with AT TORBI 709M 4-haptic toric IOL
Study NCT04035668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: Remibrutinib 100 mg was administered orally as two 50 mg hard gelatin capsules. Patients in the remibrutinib 100 mg bid dose group took 2 capsules of active medication in the morning and 2 capsules of active medication in the evening. Patients in the remibrutinib 100 mg qd dose group took 2 capsules of active medication in the morning and 2 capsules of the placebo in the evening.
Study NCT04035668 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
Study NCT04035668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was administered orally as two hard gelatin capsules. Patients in the placebo dose group took 2 capsules of placebo in the morning and 2 capsules of placebo in the evening.
Study NCT01691352 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wick dressing
Description: Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
Study NCT01691352 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: No Wick
Description: Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
Study NCT02571751 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UNIGEL Silicone Gel-Filled Breast Implant
Study NCT00579501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.5 mg/m\^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
Study NCT00579501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
Study NCT01549743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Celecoxib 200mg will be administered orally twice a day for 3 days
Study NCT01549743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rebamipide
Description: Rebamipide 100mg will be administered orally three times a day for 3 days
Study NCT04528706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIN-102
Description: Once-daily dosing with a volume specified by the pharmacokineteic specialist to achive the desired plasma exposure. Min-102 Oral suspension, strength 15mg/ml.
Study NCT03915340 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propafenone
Description: Propafenone is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 300 mg of propafenone hydrochloride.
Study NCT03915340 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Rytmonorm
Description: Rytmonorm is manufactured by Famar Lyon, France (MAH: Mylan Healthcare GmbH, Germany). Each tablet contains 300 mg of propafenone hydrochloride.
Study NCT00465816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix (Meningococcal vaccine 134612)
Description: Single dose intramuscular injection
Study NCT00465816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Nimenrix (Meningococcal vaccine 134612)
Description: Single dose intramuscular injection
Study NCT00465816 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: 3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
Study NCT00465816 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Twinrix
Description: 3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
Study NCT01129232 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAD-alum
Description: 20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
Study NCT01129232 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
Study NCT00703950 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cup feeding
Description: Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
Study NCT00703950 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bottle feeding
Description: bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
Study NCT02011698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation
Study NCT02011698 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation
Study NCT02011698 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation
Study NCT04583046 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline inhalation
Description: When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated (T0). After 20 minutes of applying one-lung ventilation, measure ABGA and VBGA (T1). Apply normal saline inhalation for control group and measure ABGA at the time of 20 min after normal saline inhalation has finished (T2).